Orchid Chemicals and Pharmaceuticals Ltd

Sholinganallur, India

Orchid Chemicals and Pharmaceuticals Ltd

Sholinganallur, India
SEARCH FILTERS
Time filter
Source Type

Rajakumar P.,University of Madras | Padmanabhan R.,Orchid Chemicals and Pharmaceuticals Ltd
Australian Journal of Chemistry | Year: 2012

The synthesis of novel N-tosyl tetraaza cyclophanes and N-tosyl diaza cyclophane incorporating m-terphenyl as spacer units is described. Anti-arthritic activity was studied by inhibition of the protein denaturation method (bovine serum albumin). All the N-tosyl aza cyclophanes exhibit excellent anti-arthritic activity. Anti-inflammatory activity of the synthesized cyclophanes was investigated using the human red blood cells (HRBC) membrane stabilization method and some of the N-tosyl aza cyclophanes exhibited good anti-inflammatory activity. © 2012 CSIRO.


Rajakumar P.,University of Madras | Padmanabhan R.,Orchid Chemicals and Pharmaceuticals Ltd.
Tetrahedron | Year: 2011

A series of mono, tricyclic cyclophane tetraamides and cyclophane sulfonamides have been synthesized and characterized from spectral and XRD studies. All the cyclophane amides form charge transfer (CT) complex with TCNQ. The cyclophane amides show moderate to good anti-inflammatory activity. Some of them were active against Gram positive (Klebsiella pneumonia) and Gram negative (Escherichia coli and Staphylococcus aureus) human pathogens. © 2011 Elsevier Ltd. All rights reserved.


Rajakumar P.,University of Madras | Padmanabhan R.,Orchid Chemicals and Pharmaceuticals Ltd
Tetrahedron Letters | Year: 2010

A series of tricyclic tetraamides have been synthesized and were characterized from spectral and XRD studies. XRD studies revealed that the pyridine-based tricyclic cyclophane amide exists with twisted phenyl rings. All the cyclophane compounds form charge-transfer (CT) complexes with TCNQ. Metal ion complexation studies show that the cyclophane amides are more selective towards Cu(II) ions rather than Ni(II) and Cd(II) ions. © 2010 Elsevier Ltd. All rights reserved.


Ponpandian T.,Madurai Kamaraj University | Ponpandian T.,Orchid Chemicals and Pharmaceuticals Ltd | Muthusubramanian S.,Madurai Kamaraj University
Tetrahedron Letters | Year: 2012

The efficient synthesis of 2-arylindoles and 6H-isoindolo[2,1-a]indol-6-one through copper catalysed domino sp-sp 2 decarboxylative cross-coupling and subsequent cyclisation reactions of arylpropiolic acids with 2-iodotrifluoroacetanilide has been described. This methodology also demonstrates that indolo[1,2-c]quinazolin-6(5H)-one can be obtained with the elimination of trifluoromethyl anion. © 2012 Elsevier Ltd. All rights reserved.


Selvaraj S.,SASTRA University | Mohan A.,SASTRA University | Narayanan S.,Orchid Chemicals and Pharmaceuticals Ltd. | Sethuraman S.,SASTRA University | Krishnan U.M.,SASTRA University
Journal of Medicinal Chemistry | Year: 2013

The present study investigates dose-dependent effects of trans-resveratrol on the membrane fluidity using planar lipid bilayer and liposome models. The complex admittance plots obtained for the lipid bilayer show that resveratrol below 60 μM preferentially interacts with the polar headgroups at the membrane-electrolyte interface, leading to enhanced membrane admittance and vice versa at higher concentrations (>60 μM). This was confirmed using solid-state 13C and 31P NMR studies and membrane fluidization studies. The localization of resveratrol in the membrane bilayer was found to alter the membrane rigidity, which resulted in a dose-dependent blebbing and lysis of erythrocytes. The protective effect of trans-resveratrol against DPPH also confirms that its localization in the hydrophobic region prevents lipid peroxidation. The cytotoxic effect of resveratrol on a breast cancer cell line also displays a progressive pattern, indicating possible correlation with its membrane rigidifying properties and localization in the lipid bilayer. © 2013 American Chemical Society.


Praveen C.,CSIR - Central Leather Research Institute | Parthasarathy K.,Orchid Chemicals and Pharmaceuticals Ltd. | Perumal P.T.,CSIR - Central Leather Research Institute
Synlett | Year: 2010

An unprecedented TfOH-promoted tandem ring-closure-aryl-migration of 2′-amino chalcone epoxide leading to 3-aryl-4(1H)-quinolones (azaisoflavones) was achieved. The outcome of the reaction was confirmed by NMR analysis and rationalized through the intermediacy of a phenonium ion. This synthetic protocol furnishes azaisoflavones straightforwardly from simple starting materials under mild conditions. © Georg Thieme Verlag Stuttgart New York.


Mohan A.,SASTRA University | Narayanan S.,Orchid Chemicals and Pharmaceuticals Ltd. | Sethuraman S.,SASTRA University | Krishnan U.M.,SASTRA University
Anti-Cancer Agents in Medicinal Chemistry | Year: 2013

The investigation of chemotherapeutic agents for the treatment of cancer since the early 1940s has resulted in the discovery of over 50 drugs till date. However, most of these drugs result in severe side effects causing physical and mental trauma to patients. In order to eliminate the side effects, search for better and safer drugs has been ongoing for several decades, which has resulted in the discovery of anti-cancer properties of many phytochemicals. Polyphenols represent a unique class of phytochemicals that possess excellent anti- oxidant, anti-inflammatory properties and also modulate cell signalling pathways leading to anti-cancer effects. However, the use of these compounds as anti-cancer agents is not as effective and hence combinations of chemotherapeutic drugs with these molecules have been attempted. Promising results in vitro and in vivo experiments while using combinations of polyphenols and chemotherapeutic agents open up new avenues for the discovery of the ideal drug combinations for cancer therapy. This review highlights the efficacy of the combination of phytochemicals with synthetic anti-neoplastic drugs over the conventional combinations of anti-neoplastic drugs and the possible interventions in the clinical settings. The review also discusses the inclusion of polyphenols in emerging therapeutic modalities like nanotechnology and photodynamic therapy. © 2013 Bentham Science Publishers.


Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.


Patent
Orchid Chemicals and Pharmaceuticals Ltd | Date: 2013-02-26

Pyrimidine compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof, are useful are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases and in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohns disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever.


Patent
Orchid Chemicals and Pharmaceuticals Ltd | Date: 2016-02-24

Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.

Loading Orchid Chemicals and Pharmaceuticals Ltd collaborators
Loading Orchid Chemicals and Pharmaceuticals Ltd collaborators